Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Share Price

Equities

1349

CNE1000000W4

Pharmaceuticals

Market Closed - Hong Kong S.E. 01:38:22 29/04/2024 pm IST 5-day change 1st Jan Change
2.18 HKD +0.46% Intraday chart for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. +3.32% -14.51%

Financials

Sales 2022 1.03B 143M 1.12B 11.89B Sales 2023 851M 118M 921M 9.81B Capitalization 7.32B 1.01B 7.93B 84.46B
Net income 2022 138M 19.08M 149M 1.59B Net income 2023 109M 15.07M 118M 1.26B EV / Sales 2022 5.52 x
Net cash position 2022 1.16B 161M 1.26B 13.43B Net cash position 2023 1.18B 163M 1.28B 13.59B EV / Sales 2023 7.22 x
P/E ratio 2022
23.6 x
P/E ratio 2023
22.1 x
Employees 948
Yield 2022
2.28%
Yield 2023
3.02%
Free-Float 45.47%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan MT
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023 MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024 CI
Fudan-Zhangjiang Bio's 2023 Profit Falls MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan MT
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products MT
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China MT
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug CI
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3 MT
More news
1 day+0.46%
1 week+3.32%
Current month+1.40%
1 month+0.93%
3 months-3.11%
6 months-16.79%
Current year-14.51%
More quotes
1 week
2.08
Extreme 2.08
2.24
1 month
2.03
Extreme 2.03
2.24
Current year
2.03
Extreme 2.03
2.59
1 year
2.03
Extreme 2.03
3.18
3 years
2.03
Extreme 2.03
5.73
5 years
2.03
Extreme 2.03
9.26
10 years
2.03
Extreme 2.03
12.64
More quotes
Managers TitleAgeSince
Founder 55 11/96/11
Founder 54 11/96/11
Director of Finance/CFO 43 01/10/01
Members of the board TitleAgeSince
Director/Board Member 68 30/13/30
Director/Board Member 51 29/12/29
Founder 54 11/96/11
More insiders
Date Price Change Volume
29/24/29 2.18 +0.46% 1 168 000
26/24/26 2.17 +2.36% 1,042,000
25/24/25 2.12 0.00% 643,000
24/24/24 2.12 +0.47% 504,000
23/24/23 2.11 0.00% 294,000

Delayed Quote Hong Kong S.E., April 29, 2024 at 01:38 pm IST

More quotes
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.
More about the company

Annual profits - Rate of surprise